{"filing":{"accession_number":"0001193125-26-389829","cik":"0001595097","ticker":"CRBP","company_name":"Corbus Pharmaceuticals Holdings, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"crbp-20260914.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526389829/crbp-20260914.htm"},"events":[{"id":33102,"run_id":30426,"accession_number":"0001193125-26-389829","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Corbus Pharmaceuticals announced positive topline data from the CANYON-1 Phase 1b clinical trial of CRB-913 for obesity treatment, demonstrating statistically significant weight loss (5% at 60 mg dose) and favorable safety profile, with data selected for late-breaking presentation at ObesityWeek® 2026. This material clinical development milestone affects investor assessment of the company's lead obesity program's development trajectory and commercial potential.","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36449,"accession_number":"0001193125-26-389829","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Corbus Pharmaceuticals disclosed positive Phase 1b clinical trial results for CRB-913 in obesity treatment, including statistically significant weight loss (5% at 60 mg after 12 weeks) and favorable safety profile. The data was selected for late-breaking presentation at ObesityWeek® 2026. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the drug candidate's development trajectory and commercial potential, but does not fit the specific financial, governance, or legal event categories—it is an operational/strategic clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:07:41.658232+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36450,"accession_number":"0001193125-26-389829","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Corbus Pharmaceuticals announced positive topline data from the CANYON-1 Phase 1b clinical trial of CRB-913 for obesity treatment, demonstrating statistically significant weight loss (5% at 60 mg dose) and favorable safety profile. This is a material clinical development milestone for a clinical-stage company's lead obesity program, affecting investor assessment of the company's pipeline progress and competitive positioning, but does not fit the specific earnings_release category (which typically applies to financial results disclosures) nor any other defined event type. The disclosure centers on operational/clinical progress rather than financial results, M\u0026A, governance, or other specific material event categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:07:41.658232+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36449,"accession_number":"0001193125-26-389829","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Corbus Pharmaceuticals disclosed positive Phase 1b clinical trial results for CRB-913 in obesity treatment, including statistically significant weight loss (5% at 60 mg after 12 weeks) and favorable safety profile. The data was selected for late-breaking presentation at ObesityWeek® 2026. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the drug candidate's development trajectory and commercial potential, but does not fit the specific financial, governance, or legal event categories—it is an operational/strategic clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:07:41.658232+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-09-14"},{"id":36450,"accession_number":"0001193125-26-389829","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Corbus Pharmaceuticals announced positive topline data from the CANYON-1 Phase 1b clinical trial of CRB-913 for obesity treatment, demonstrating statistically significant weight loss (5% at 60 mg dose) and favorable safety profile. This is a material clinical development milestone for a clinical-stage company's lead obesity program, affecting investor assessment of the company's pipeline progress and competitive positioning, but does not fit the specific earnings_release category (which typically applies to financial results disclosures) nor any other defined event type. The disclosure centers on operational/clinical progress rather than financial results, M\u0026A, governance, or other specific material event categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:07:41.658232+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-09-14"}]}